Format

Send to

Choose Destination
Laryngoscope. 2010 Feb;120(2):432-5. doi: 10.1002/lary.20757.

Hereditary hemorrhagic telangiectasia/avastin.

Author information

1
Department of Head and Neck Surgery, San Diego School of Medicine, University of California, VA San Diego Healthcare System, San Diego, California 92161, USA. tdavidson@ucsd.edu

Abstract

This is the first scientific report of hereditary hemorrhagic telangiectasia (HHT) epistaxis treatment by intranasal spraying of the vascular endothelial growth factor (VEGF) inhibitor bevacizumab (Avastin). Epistaxis in patients with HHT is a morbid, mortal condition that is difficult and unpleasant to manage. Nasal telangiectasia growth is modulated by VEGF, which is elevated in HHT patients. Bevacizumab is a VEGF inhibitor that diminishes epistaxis when administered intravenously or injected locally, or as reported here when sprayed topically onto the nasal mucosa.

PMID:
19998344
DOI:
10.1002/lary.20757
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center